Clearance of the very high levels of plasma viremia that generally accompany acute infection with HIV is a consequence of host immune responses to the virus. Despite this ability of the immune system to mediate a profound decline in viral burden, HIV eventually evades immunologic control. CD4+ T helper responses have been shown to be necessary for containment of chronic viral infections, and one hallmark of HIV infection is the deficiency from very early in disease of a substantial CD4+ T cell response to the virus. Thus, strategies to correct this deficiency, particularly if combined with new antiretroviral drug therapies, might result in improved control of HIV. Our laboratory has developed methods to isolate, clone, and expand virus-specific CD4+ T cells in vitro, and has demonstrated that adoptive transfer of such T cells can reconstitute deficient CD4+ T cell responses in vivo. There are several obstacles to applying this technology to the treatment of HIV-- most significantly, transferred HIV-specific CD4+ T cells would likely localize to sites of infection and be at risk for rapid deletion. Therefore, methods are being explored to modify these cells prior to infusion by the introduction of genes that render them resistant to HIV infection, a technique termed intracellular immunization (IC-imm). The administration to HIV-infected individuals of large numbers of such autologous, protected, HIV-specific CD4+ T cells should provide a unique opportunity to assess the impact of a competent immune response on HIV. The proposed studies include preclinical experiments to develop improved molecular strategies to protect CD4+ T cells from infection by HIV, and clinical trials to determine the in vivo biologic activity of CD4+ T cells expressing these genes.
The specific aims are to: (1) evaluate in vitro the ability of IC-imm genes designed to prevent infection to preserve the survival and function of HIV-specific CD4+ T cells exposed to infectious HIV and to compare this antiviral activity with IC-imm genes designed to inhabit viral replication; (2) evaluate the ability of IC-imm genes to protect and preserve the function of adoptive transferred HIV-specific CD4+ T cells in patients with CD4+ counts greater than 200 and with greater than 1000 copies of HIV/ml; (3) evaluate the ability of adoptively-transferred gp-160-specific CD4+ T cell clones expressing IC- imm genes to persist and modulate antiviral immunity in individuals on anti-retroviral therapy with CD4+ counts greater than 200 and plasma viremia between 50 and 500 copies of HIV/ml; and (4) determine if the transfer of HIV-specific CD4+ T cells resistant to HIV and of HIV-specific CD8+ CTL in patients with primary HIV infection can provide persistent cellular immunity to HIV.

Project Start
2000-09-01
Project End
2001-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
3
Fiscal Year
2000
Total Cost
$251,290
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Pollack, Seth M; Jones, Robin L; Farrar, Erik A et al. (2014) Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer 2:36
Ochsenbein, Adrian F; Riddell, Stanley R; Brown, Michele et al. (2004) CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med 200:1407-17
Cooper, Laurence J N; Topp, Max S; Pinzon, Cris et al. (2004) Enhanced transgene expression in quiescent and activated human CD8+ T cells. Hum Gene Ther 15:648-58
Topp, Max S; Riddell, Stanley R; Akatsuka, Yoshiki et al. (2003) Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med 198:947-55
Cheng, Laurence E; Ohlen, Claes; Nelson, Brad H et al. (2002) Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc Natl Acad Sci U S A 99:3001-6
Lewinsohn, Deborah A; Lines, Rebecca; Lewinsohn, David M et al. (2002) HIV-1 Vpr does not inhibit CTL-mediated apoptosis of HIV-1 infected cells. Virology 294:13-21
Cheng, Laurence E; Greenberg, Philip D (2002) Selective delivery of augmented IL-2 receptor signals to responding CD8+ T cells increases the size of the acute antiviral response and of the resulting memory T cell pool. J Immunol 169:4990-7
Truong, Hong-Ha M; Berrey, M Michelle; Shea, Theresa et al. (2002) Concordance between HIV source partner identification and molecular confirmation in acute retroviral syndrome. J Acquir Immune Defic Syndr 29:232-43
Bonini, C; Lee, S P; Riddell, S R et al. (2001) Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 166:5250-7
Georges, G E; Storb, R; Bruno, B et al. (2001) Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes. Blood 98:3447-55

Showing the most recent 10 out of 13 publications